Clinical Trials Sponsored by AJI Pharma USA

Total 326 results

Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma

United States, Canada, Italy, Finland
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

Phase I Biomarker Study (BMS-936558)

Renal Cell Carcinoma

United States, France, Spain
National Jewish Health
Fidia Pharma USA Inc.

Recruiting

Synovial Fluid Biomarkers Pre and Post Hymovis Knee Injection

Knee Osteoarthritis

United States
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants

Kidney Cancer | Renal Cancer

Japan
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan (LIGHT-NING)

Non-Small Cell Lung Cancer

Japan
Bristol-Myers Squibb
Ono Pharma USA Inc

Completed

Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread

Cancer of Head and Neck | Cancer of the Head | Cancer of the Neck

Japan
UCB Pharma SA

Completed

Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy

Epilepsy

United States, Belgium, Czechia, France, Germany, Hungary, Ireland, Italy, Mexico, Poland, Spain, United Kingdom
UCB Pharma SA

Completed

Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam

Epilepsy, Partial

Canada, United States
UCB Pharma SA

Completed

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

Epilepsy

Belgium, Finland, France, Germany, Hungary, India, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom
UCB Pharma SA

Completed

Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy

Generalized Epilepsy
UCB Pharma SA

Completed

Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)

Dermatitis, Atopic
UCB Pharma SA

Completed

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] (PRECiSE 3)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine, Canada and more
UCB Pharma SA

Completed

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults

Unverricht-Lundborg Disease

France, Italy, Sweden, Finland, Netherlands, Tunisia, Réunion
UCB Pharma SA

Completed

Bioavailability/Bioequivalence Study Between Lacosamide Tablet and Solution for Infusion in Healthy Japanese Subjects

Healthy Volunteers

United Kingdom
UCB Pharma SA

Terminated

Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease (REFRESH-PD)

Advanced Idiopathic Parkinson's Disease

United Kingdom
UCB Pharma SA

Completed

Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes

Narcolepsy With Cataplexy

Belgium
UCB Pharma SA

Completed

A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects

Healthy Volunteers

Netherlands
UCB Pharma SA

Completed

Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)

Epilepsy

United States, France, Germany, Spain, United Kingdom
UCB Pharma SA

Completed

Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy

Epilepsy

Ukraine, Belgium, Germany, Hong Kong, India, South Africa, Taiwan, Sweden, Korea, Republic of, Singapore, Russian Federation, Austria, Italy, Norway, Czechia
UCB Pharma SA

Completed

Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers

Healthy Volunteers

Netherlands
UCB Pharma SA

Completed

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors (NexT)

Rheumatoid Arthritis

Germany
UCB Pharma SA

Completed

Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.

Epilepsy, Tonic-clonic

Poland, Sweden, Hungary, Czechia
UCB Pharma SA

Completed

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease (PRECiSE 4)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine
UCB Pharma SA

Completed

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (C-early)

Rheumatoid Arthritis

Germany, United States, Argentina, Australia, Austria, Belgium, Canada, Colombia, Czechia, France, Hungary, Ireland, Italy, Mexico, Monaco, Netherlands, Poland, Romania, Spain, Sweden, Switzerland, United Kingdom
UCB Pharma SA

Completed

Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

Epilepsy

United States, France, Germany, Spain
UCB Pharma SA

Completed

Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures

Epilepsy | Partial Seizures

China
UCB Pharma SA

Completed

Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy

Epilepsy

France, United States, Mexico, Turkey, Belgium, Germany
UCB Pharma SA

Completed

Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations

Healthy

China
MEDA Pharma GmbH & Co. KG
ClinResearch, GmbH; Trio Clinical Research, LLC, Raleigh, USA; NuCara Pharmacy... and other collaborators

Completed

Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg

Asthma

United States
Ono Pharma USA Inc

Completed

Placebo-Controlled Study of ONO-2333Ms in Patients With Recurrent Major Depressive Disorder

Major Depressive Disorder

United States
Bristol-Myers Squibb
Medarex; Ono Pharma USA Inc

Completed

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Malignant Melanoma

United States
Teikoku Pharma USA, Inc.
Premier Research Group plc

Completed

Dexmedetomidine Transdermal System (DMTS) for Post-Operative Analgesia Following Bunionectomy (DMTS)

Pain, Postoperative

Australia
Ono Pharma USA Inc

Terminated

A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia

Chemotherapy-Induced Thrombocytopenia

United States, Korea, Republic of, Russian Federation
Ono Pharma USA Inc
Ono Pharmaceutical Co. Ltd

Completed

ONO-2952 Single-dose PET Study in Healthy Adult Subjects

Healthy Adult Subjects

United States
Ono Pharma USA Inc

Completed

Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan

Postoperative Supraventricular Tachyarrythmia
Ono Pharma USA Inc

Completed

Single Dose Escalation Study of ONO-9054 in Healthy Volunteers

Healthy Adult Subjects

United States
Ono Pharma USA Inc

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-6950 in Healthy Adult Subjects

Healthy Adult Subjects

United States
Medesis Pharma SA

Terminated

NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)

COVID-19 Pandemic

Brazil
OM Pharma SA

Terminated

Immunomodulation by OM-85 (Broncho-Vaxom) in Early AD

Atopic Dermatitis

Germany, France, Poland, Netherlands
Labatec Pharma SA

Unknown

Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes

Osteoporosis, Postmenopausal

Switzerland
Memorial Sloan Kettering Cancer Center
Chugai Pharma USA

Recruiting

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

Primary Extra-cranial Solid Tumor | Recurrent or Refractory Glypican 3 (GPC3)

United States
Ono Pharma USA Inc

Terminated

Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)

Irritable Bowel Syndrome (IBS)

United States
Ono Pharma USA Inc
Ono Pharmaceutical Co. Ltd

Completed

A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients

Asthma

United States
Ono Pharma USA Inc
Ono Pharmaceutical Co. Ltd

Completed

A Placebo and Active Controlled Study of ONO-6950 Following Allergen Challenge in Patients With Asthma

Asthma

Canada
Ono Pharma USA Inc

Completed

A Phase II Study to Evaluate the Effects of Oral ONO-5129 in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Ono Pharma USA Inc

Completed

Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

Healthy

United States
Ono Pharma USA Inc

Completed

Controlled Study of ONO-5334 in Postmenopausal Women With Osteopenia or Osteoporosis

Osteoporosis | Osteopenia

Netherlands
Ono Pharma USA Inc

Completed

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)

Irritable Bowel Syndrome (IBS)

United States
Ono Pharma USA Inc

Completed

A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (DreaMS)

Multiple Sclerosis

United States, Belgium, Canada, Czech Republic, Germany, Greece, Japan, Poland, Russian Federation, Spain, Ukraine
Ono Pharma USA Inc
Ono Pharmaceutical Co. Ltd

Completed

An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment

Healthy | Hepatic Impairment

United States

3

Subscribe